PMID- 24532277
OWN - NLM
STAT- MEDLINE
DCOM- 20140505
LR  - 20211021
IS  - 1526-632X (Electronic)
IS  - 0028-3878 (Print)
IS  - 0028-3878 (Linking)
VI  - 82
IP  - 11
DP  - 2014 Mar 18
TI  - Daclizumab-induced adverse events in multiple organ systems in multiple 
      sclerosis.
PG  - 984-8
LID - 10.1212/WNL.0000000000000222 [doi]
AB  - OBJECTIVE: To report 3 patients with multiple sclerosis (MS) who presented with 
      daclizumab-related adverse events (AEs) in multiple organ systems. METHODS: A 
      retrospective chart review was performed of patients with MS who had clinical and 
      histopathologic findings suggestive of daclizumab-induced AEs between 2004 and 
      2010 at the Johns Hopkins MS Clinic. This study met criteria for exemption from 
      review from the institutional review board. RESULTS: Of 20 total patients with MS 
      who had been treated with daclizumab, 3 patients with clinical and 
      histopathologic findings suggestive of daclizumab-induced AEs were identified. 
      All patients were treated with Zenapax (1 mg/kg monthly IV infusions) outside of 
      a clinical trial setting. Clinical manifestations after a mean treatment duration 
      of 20 months consisted of diffuse rash and alopecia, diffuse lymphadenopathy, and 
      breast nodules. Tissue histopathology demonstrated lymphocytic infiltrates with 
      CD56-expressing cells in 2 patients (lymph node, breast nodule). On daclizumab 
      discontinuation, the rash/alopecia and diffuse lymphadenopathy resolved, while 
      the breast nodules stabilized. CONCLUSIONS: Daclizumab-induced AEs can occur in 
      various organ systems after a relatively prolonged duration of exposure and 
      require clinician awareness. Future studies are needed to better understand the 
      relationship between natural killer cells and daclizumab-related AEs.
FAU - Oh, Jiwon
AU  - Oh J
AD  - From the Department of Neurology (J. Oh, S.S., P.A.C., S.D.N.), Johns Hopkins 
      University, Baltimore; and Neuroimmunology Branch (I.C., J. Ohayon, B.B.), 
      National Institute of Neurological Disorders and Stroke, Bethesda, MD.
FAU - Saidha, Shiv
AU  - Saidha S
FAU - Cortese, Irene
AU  - Cortese I
FAU - Ohayon, Joan
AU  - Ohayon J
FAU - Bielekova, Bibiana
AU  - Bielekova B
FAU - Calabresi, Peter A
AU  - Calabresi PA
FAU - Newsome, Scott D
AU  - Newsome SD
LA  - eng
GR  - UL1 TR001079/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140214
PL  - United States
TA  - Neurology
JT  - Neurology
JID - 0401060
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antigens, CD)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Immunosuppressive Agents)
RN  - CUJ2MVI71Y (Daclizumab)
SB  - IM
MH  - AIDS-Related Complex/*chemically induced
MH  - Adult
MH  - Antibodies, Monoclonal, Humanized/*adverse effects
MH  - Antigens, CD/metabolism
MH  - Breast/drug effects/pathology
MH  - Daclizumab
MH  - Female
MH  - Humans
MH  - Immunoglobulin G/*adverse effects
MH  - Immunosuppressive Agents/*adverse effects
MH  - Leukemic Infiltration/chemically induced
MH  - Lymph Nodes/drug effects/pathology
MH  - Male
MH  - Middle Aged
MH  - Multiple Sclerosis/drug therapy
MH  - Retrospective Studies
PMC - PMC3963003
EDAT- 2014/02/18 06:00
MHDA- 2014/05/06 06:00
PMCR- 2015/03/18
CRDT- 2014/02/18 06:00
PHST- 2014/02/18 06:00 [entrez]
PHST- 2014/02/18 06:00 [pubmed]
PHST- 2014/05/06 06:00 [medline]
PHST- 2015/03/18 00:00 [pmc-release]
AID - WNL.0000000000000222 [pii]
AID - NEUROLOGY2013549840 [pii]
AID - 10.1212/WNL.0000000000000222 [doi]
PST - ppublish
SO  - Neurology. 2014 Mar 18;82(11):984-8. doi: 10.1212/WNL.0000000000000222. Epub 2014 
      Feb 14.